

AO 120 (Rev. 08/10)

TO: <b style="text-align: center;">Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	---

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court _____ on the following

Trademarks or Patents. (the patent action involves 35 U.S.C. § 292.):

DOCKET NO.	DATE FILED	U.S. DISTRICT COURT
PLAINTIFF		DEFENDANT
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1		
2		
3		
4		
5		

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT

CLERK	(BY) DEPUTY CLERK	DATE
-------	-------------------	------



US008242158B1

(12) **United States Patent**
Roychowdhury et al.

(10) **Patent No.:** **US 8,242,158 B1**
(45) **Date of Patent:** **Aug. 14, 2012**

(54) **DEXMEDETOMIDINE PREMIX
FORMULATION**

(75) Inventors: **Priyanka Roychowdhury**, San Rafael,
CA (US); **Robert A. Cedergren**,
Libertyville, IL (US)

(73) Assignee: **Hospira, Inc.**, Lake Forest, IL (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/343,672**

(22) Filed: **Jan. 4, 2012**

(51) **Int. Cl.**
A61K 31/164 (2006.01)

(52) **U.S. Cl.** **514/396**; 514/816

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,344,840 A 9/1994 Maze et al.
6,716,867 B1 4/2004 Aantaa et al.
2010/0197694 A1 8/2010 Horn
2011/0152271 A1 6/2011 Horn
2011/0230534 A1 9/2011 Miyawaki et al.

FOREIGN PATENT DOCUMENTS

WO WO 2010/031819 3/2010

OTHER PUBLICATIONS

“Dexmedetomidine HCL Draft Labeling: Precedex™
Dexmedetomidine Hydrochloride Injection,” FDA approved label,
dated Dec. 17, 1999, and available online Jul. 26, 2001, pp. 1-13.
Downloaded from < http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex_pnttbl.pdf> on Jan. 4, 2012.
FDA Memorandum from Cynthia G. McCormick, M.D., Director,
Division on Anesthetics, Critical Care and Addiction Drug Products,
dated Nov. 30, 1999, in connection with the Medical Reviews of the
Precedex (dexmedetomidine hydrochloride injection) Application
No. 21-038 submitted to the FDA by Abbott Laboratories on Dec. 18,
1998, and available on the FDA website Jul. 26, 2001. Downloaded
on Mar. 7, 2012 from < http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex.cfm>.

Primary Examiner — James D Anderson

Assistant Examiner — Gregg Polansky

(74) *Attorney, Agent, or Firm* — Baker Botts LLP

(57) **ABSTRACT**

The presently disclosed subject matter relates to pharmaceu-
tical compositions comprising dexmedetomidine or a phar-
maceutically acceptable salt thereof wherein the composition
is formulated as a liquid for parenteral administration to a
subject, and wherein the composition is disposed within a
sealed container as a premixture. The pharmaceutical com-
positions can be used, for example, in perioperative care of a
patient or for sedation.

4 Claims, No Drawings



US008338470B1

(12) **United States Patent**
Roychowdhury et al.(10) **Patent No.:** **US 8,338,470 B1**
(45) **Date of Patent:** ***Dec. 25, 2012**(54) **DEXMEDETOMIDINE PREMIX
FORMULATION**(75) Inventors: **Priyanka Roychowdhury**, San Rafael,
CA (US); **Robert A. Cedergren**,
Libertyville, IL (US)(73) Assignee: **Hospira, Inc.**, Lake Forest, IL (US)(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.This patent is subject to a terminal dis-
claimer.(21) Appl. No.: **13/541,524**(22) Filed: **Jul. 3, 2012****Related U.S. Application Data**(63) Continuation of application No. 13/343,672, filed on
Jan. 4, 2012, now Pat. No. 8,242,158.(51) **Int. Cl.**
A61K 31/164 (2006.01)(52) **U.S. Cl.** **514/396; 514/816**(58) **Field of Classification Search** None
See application file for complete search history.(56) **References Cited**

U.S. PATENT DOCUMENTS

5,344,840	A	9/1994	Maze et al.
5,716,988	A *	2/1998	Ibrahim et al.
6,716,867	B1	4/2004	Aantaa et al.
6,806,291	B1 *	10/2004	Sunkel et al.
2010/0094219	A1	4/2010	Kriesel et al.
2010/0197694	A1	8/2010	Horn
2010/0305160	A1	12/2010	Brummett
2010/0326868	A1	12/2010	McClain et al.
2011/0152271	A1	6/2011	Horn
2011/0230534	A1	9/2011	Miyawaki et al.
2011/0269666	A1	11/2011	Quintin

FOREIGN PATENT DOCUMENTS

WO WO 2010/031819 3/2010

OTHER PUBLICATIONS

Precedex® Package Insert, Document EN-2680, Hospira, Inc., Sep.
2010, downloaded on Aug. 10, 2012 from "www.precedex.com/wp-
content/uploads/2010/11/Precedex_Pl.pdf", pp. 1-24.*Xylocaine® Package Insert, AstraZeneca LP, 2001 and 2007, down-
loaded on Aug. 10, 2012 from "www.pdr3d.com/print.php?c=4818",
pp. 1-30.*Venn et al., *British Journal of Anaesthesia*, 2002, vol. 88(5), pp.
669-675.*Unger et al., *Biomaterials*, vol. 22, 2001, pp. 2031-2037.*

U.S. Appl. No. 13/343,672, filed Jan. 4, 2012.

U.S. Appl. No. 13/343,672, Apr. 18, 2012 Notice of Allowance.
U.S. Appl. No. 13/343,672, Apr. 18, 2012 Examiner Initiated Inter-
view Summary.U.S. Appl. No. 13/343,672, Mar. 13, 2012 Response to Office Action
and Statement of the Substance of the Interview.U.S. Appl. No. 13/343,672, Mar. 6, 2012 Applicant Initiated Inter-
view Summary.

U.S. Appl. No. 13/343,672, Feb. 13, 2012 Non-Final Rejection.

U.S. Appl. No. 13/343,672, Jan. 31, 2012 Decision on Petition to
Make Special for New Application Under 37 C.F.R. § 1.102 & M.P.
E.P. § 708.02.FDA Memorandum from Cynthia G. McCoirnick, M.D., Director,
Division of Anesthetics, Critical Care and Addiction Drug Products,
dated Nov. 30, 1999, in connection with the Medical Reviews of the
Precedex (dexmedetomidine hydrochloride injection) Application
No. 21-038 submitted to the FDA by Abbott Laboratories on Dec. 18,
1998, and available on the FDA website Jul. 26, 2001. Downloaded
on Mar. 7, 2012 from <http://www.accessdata.fda.gov/drugsatfda_
docs/nda/99/21-038_Precedex.cfm>."Dexmedetomidine HCL Draft Labeling: Precedex™
Dexmedetomidine Hydrochloride Injection," FDA approved label,
dated Dec. 17, 1999, and available online Jul. 26, 2001, pp. 1-13.
Downloaded from <http://www.accessdata.fda.gov/drugsatfda_
docs/nda/99/21-038_Precedex_pntlbl.pdf> on Jan. 4, 2012.Short, "Use of dexmedetomidine for primary sedation in a general
intensive care unit." *Critical Care Nurse* (online), Epub Oct. 29, 2009
[Retrieved on Aug. 13, 2012], vol. 30, No. 1, pp. 29-38, Feb. 2010,
Retrieved from the internet: <URL: http://ccn.aacnjournals.org/con-
tent/30/1/29>.International Search Report and Written Opinion in International
Application No. PCT/US2012/042940, mailed Aug. 24, 2012.Petersen, "Trends in Pharmaceutical Primary Packaging for
Injectables—Solutions for New Challenges," *Drug Development and
Delivery*, Issue Date: Sep. 2012, Posted on: Sep. 5, 2012. Down-
loaded on Sep. 14, 2012 from < http://http://www.drug-dev.com/
ME2/dirmod.asp?sid=4306B1E9C3CC4E07A4D64E23FBDB232C
&nm=Back+Issues&type=Publishing
&mod=Publications%3A%3AArticle
&mid=8F3A7027421841978F18BE895F87F791&tier=4
&id=C2347A2CEAE1422DAA7E592E47648D77 >.

* cited by examiner

Primary Examiner — Jeffrey S. Lundgren*Assistant Examiner* — Gregg Polansky(74) *Attorney, Agent, or Firm* — Baker Botts LLP(57) **ABSTRACT**The presently disclosed subject matter relates to pharmaceu-
tical compositions comprising dexmedetomidine or a phar-
maceutically acceptable salt thereof wherein the composition
is formulated as a liquid for parenteral administration to a
subject, and wherein the composition is disposed within a
sealed container as a premixture. The pharmaceutical com-
positions can be used, for example, in perioperative care of a
patient or for sedation.**7 Claims, No Drawings**



US008455527B1

(12) **United States Patent**
Roychowdhury et al.(10) **Patent No.:** **US 8,455,527 B1**
(45) **Date of Patent:** ***Jun. 4, 2013**(54) **METHODS OF TREATMENT USING A
DEXMEDETOMIDINE PREMIX
FORMULATION**(71) Applicant: **Hospira, Inc.**, Lake Forest, IL (US)(72) Inventors: **Priyanka Roychowdhury**, Foster City,
CA (US); **Robert A. Cedergren**,
Libertyville, IL (US)(73) Assignee: **Hospira, Inc.**, Lake Forest, IL (US)(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.This patent is subject to a terminal dis-
claimer.(21) Appl. No.: **13/678,148**(22) Filed: **Nov. 15, 2012****Related U.S. Application Data**(63) Continuation of application No. 13/541,524, filed on
Jul. 3, 2012, now Pat. No. 8,338,470, which is a
continuation of application No. 13/343,672, filed on
Jan. 4, 2012, now Pat. No. 8,242,158.(51) **Int. Cl.**
A61K 31/164 (2006.01)(52) **U.S. Cl.**
USPC **514/396; 514/816**(58) **Field of Classification Search**
None
See application file for complete search history.(56) **References Cited**

U.S. PATENT DOCUMENTS

4,910,214	A	3/1990	Karjalainen et al.
5,344,840	A	9/1994	Maze et al.
5,716,988	A	2/1998	Ibrahim et al.
6,716,867	B1	4/2004	Aantaa et al.
6,806,291	B1	10/2004	Sunkel et al.
2010/0094219	A1	4/2010	Kriesel et al.
2010/0197694	A1	8/2010	Horn
2010/0305160	A1	12/2010	Brummett
2010/0326868	A1	12/2010	McClain et al.
2011/0152271	A1	6/2011	Horn
2011/0230534	A1	9/2011	Miyawaki et al.
2011/0269666	A1	11/2011	Quintin

FOREIGN PATENT DOCUMENTS

WO WO 2010/031819 3/2010

OTHER PUBLICATIONS

U.S. Appl. No. 13/343,672, filed Jan. 4, 2012.
 U.S. Appl. No. 13/541,524, filed Jul. 3, 2012.
 U.S. Appl. No. 13/343,672, Apr. 18, 2012 Notice of Allowance.
 U.S. Appl. No. 13/343,672, Apr. 18, 2012 Examiner Initiated Interview Summary.
 U.S. Appl. No. 13/343,672, Mar. 13, 2012 Response to Office Action and Statement of the Substance of the Interview.
 U.S. Appl. No. 13/343,672, Mar. 6, 2012 Applicant Initiated Inter-

U.S. Appl. No. 13/343,672, Jan. 31, 2012 Decision on Petition to Make Special for New Application Under 37 C.F.R. § 1.102 & M.P. E.P. § 708.02.

U.S. Appl. No. 13/541,524, Oct. 22, 2012 Notice of Allowance.
 U.S. Appl. No. 13/541,524, Sep. 17, 2012 Response to Office Action.
 U.S. Appl. No. 13/541,524, Aug. 17, 2012 Non-Final Rejection.
 U.S. Appl. No. 13/541,524, Jul. 30, 2012 Decision on Petition to Make Special for New Application Under 37 C.F.R. § 1.102 & M.P. E.P. § 708.02.

FDA Memorandum from Cynthia G. McCormick, M.D., Director, Division of Anesthetics, Critical Care and Addiction Drug Products, dated Nov. 30, 1999, in connection with the Medical Reviews of the Precedex (dexmedetomidine hydrochloride injection) Application No. 21-038 submitted to the FDA by Abbott Laboratories on Dec. 18, 1998, and available on the FDA website Jul. 26, 2001. Downloaded on Mar. 7, 2012 from <http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex.cfm>.

Petersen, "Trends in Pharmaceutical Primary Packaging for Injectables—Solutions for New Challenges," *Drug Development and Delivery*, Issue Date: Sep. 2012, Posted on Sep. 5, 2012. Downloaded on Sep. 14, 2012 from <http://http://www.drug-dev.com/ME2/dirmod.asp?sid=4306B1E9C3CC4E07A4D64E23FBDB232C&nm=Back+Issues&type=Publishing&mod=Publications%3A%3A Article&mid=8F3A7027421841978F18BE895F87F791&tier=4&id=C2347A2CEAE1422DAA7E592E47648D77 >.

Short, "Use of dexmedetomidine for primary sedation in a general intensive care unit." *Critical Care Nurse* (online), Epub Oct. 29, 2009 [Retrieved on Aug. 13, 2012], vol. 30, No. 1, pp. 29-38, Feb. 2010, Retrieved from the internet: <URL:http://ccn.aacnjournals.org/content/30/1/29>.

International Search Report and Written Opinion in International Application No. PCT/US2012/042940, mailed Aug. 24, 2012.

Unger et al., "Adsorption of xenobiotics to plastic tubing incorporated into dynamic in vitro systems used in pharmacological research—limits and progress." *Biomaterials*, vol. 22, 2001, pp. 2031-2037.

Precedex® Package Insert, Document EN-2680, Hospira, Inc., Sep. 2010, downloaded on Aug. 10, 2012 from <URL:http://www.precedex.com/wp-content/uploads/2010/11/Precedex_PL.pdf>, pp. 1-24.

Xylocaine® Package Insert, AstraZeneca LP, 2001 and 2007, downloaded on Aug. 10, 2012 from <URL:http://www.pdr3d.com/print.php?c=4818>, pp. 1-30.

Venn et al., "Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care." *British Journal of Anaesthesia*, 2002, vol. 88(5), pp. 669-675.

"Dexmedetomidine HCL Draft Labeling: Precedex™ Dexmedetomidine Hydrochloride Injection," FDA approved label, dated Dec. 17, 1999, and available online Jul. 26, 2001, pp. 1-13, Downloaded from <http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex_pntlbl.pdf> on Jan. 4, 2012.

Primary Examiner — Jeffrey S. Lundgren*Assistant Examiner* — Gregg Polansky(74) *Attorney, Agent, or Firm* — Baker Botts, L.L.P.(57) **ABSTRACT**

The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.



US008648106B2

(12) **United States Patent**
Roychowdhury et al.(10) **Patent No.:** **US 8,648,106 B2**
(45) **Date of Patent:** ***Feb. 11, 2014**(54) **DEXMEDETOMIDINE PREMIX**
FORMULATION(71) Applicant: **Hospira, Inc.**, Lake Forest, IL (US)(72) Inventors: **Priyanka Roychowdhury**, Foster City, CA (US); **Robert A. Cedergren**, Libertyville, IL (US)(73) Assignee: **Hospira, Inc.**, Lake Forest, IL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/867,861**(22) Filed: **Apr. 22, 2013**(65) **Prior Publication Data**

US 2013/0237576 A1 Sep. 12, 2013

Related U.S. Application Data

(63) Continuation of application No. 13/678,260, filed on Nov. 15, 2012, now Pat. No. 8,436,033, which is a continuation of application No. 13/541,524, filed on Jul. 3, 2012, now Pat. No. 8,338,470, which is a continuation of application No. 13/343,672, filed on Jan. 4, 2012, now Pat. No. 8,242,158.

(51) **Int. Cl.****A61K 31/164** (2006.01)**C07D 233/56** (2006.01)(52) **U.S. Cl.**USPC **514/396**; 514/816; 548/346.1(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,910,214	A	3/1990	Karjalainen et al.
5,344,840	A	9/1994	Maze et al.
5,716,988	A	2/1998	Ibrahim et al.
6,716,867	B1	4/2004	Aantaa et al.
6,806,291	B1	10/2004	Sunkel et al.
8,242,158	B1	8/2012	Roychowdhury et al.
8,338,470	B1	12/2012	Roychowdhury et al.
8,436,033	B1	5/2013	Roychowdhury et al.
8,455,527	B1	6/2013	Roychowdhury et al.
2010/0094219	A1	4/2010	Kriesel et al.
2010/0197694	A1	8/2010	Horn
2010/0305160	A1	12/2010	Brummett
2010/0326868	A1	12/2010	McClain et al.
2011/0152271	A1	6/2011	Horn
2011/0230534	A1	9/2011	Miyawaki et al.
2011/0269666	A1	11/2011	Quintin

FOREIGN PATENT DOCUMENTS

OTHER PUBLICATIONS

U.S. Appl. No. 13/343,672, filed Jan. 4, 2012.
 U.S. Appl. No. 13/541,524, filed Jul. 3, 2012.
 U.S. Appl. No. 13/678,148, filed Nov. 15, 2012.
 U.S. Appl. No. 13/678,260, filed Nov. 15, 2012.
 U.S. Appl. No. 13/343,672, Jul. 18, 2012 Issue Fee payment.
 U.S. Appl. No. 13/343,672, Apr. 18, 2012 Notice of Allowance.
 U.S. Appl. No. 13/343,672, Mar. 13, 2012 Response to Non-Final Office Action (Accelerated Exam).
 U.S. Appl. No. 13/343,672, Feb. 13, 2012 Non-Final Office Action.
 U.S. Appl. No. 13/541,524, Nov. 20, 2012 Issue Fee payment.
 U.S. Appl. No. 13/541,524, Oct. 22, 2012 Notice of Allowance.
 U.S. Appl. No. 13/541,524, Sep. 17, 2012 Response to Non-Final Office Action and Terminal Disclaimer filed.
 U.S. Appl. No. 13/541,524, Aug. 17, 2012 Non-Final Office Action.
 U.S. Appl. No. 13/678,148, May 9, 2013 Issue Fee payment.
 U.S. Appl. No. 13/678,148, Jan. 11, 2013 Notice of Allowance.
 U.S. Appl. No. 13/678,260, Apr. 8, 2013 Issue Fee payment.
 U.S. Appl. No. 13/678,260, Jan. 8, 2013 Notice of Allowance
 "Dexmedetomidine HCL Draft Labeling: Precedex™ Dexmedetomidine Hydrochloride Injection," FDA approved label, dated Dec. 17, 1999, and available online Jul. 26, 2001, pp. 1-13. Downloaded from <http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex_pnttbl.pdf> on Jan. 4, 2012.
 FDA Memorandum from Cynthia G. McCormick, M.D., Director, Division of Anesthetics, Critical Care and Addiction Drug Products, dated Nov. 30, 1999, in connection with the Medical Reviews of the Precedex (dexmedetomidine hydrochloride injection) Application No. 21-038 submitted to the FDA by Abbott Laboratories on Dec. 18, 1998, and available on the FDA website Jul. 26, 2001. Downloaded on Mar. 7, 2012 from <http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex.dfm>.
 Petersen, "Trends in Pharmaceutical Primary Packaging for Injectables—Solutions for New Challenges," *Drug Development and Delivery*, Issue Date: Sep. 2012, Posted on: Sep. 5, 2012. Downloaded on Sep. 14, 2012 from <<http://www.drug-dev.com/ME2/dirmod.asp?mod=Publications%3A%3AArticle&mid=8F3A7027421841978F18BE895F87F791&tier=4&id=C2347A2CEAE1422DAA7E592E47648D77>>.
 Precedex® Package Insert, Document EN-2680, Hospira, Inc., Sep. 2010, downloaded on Aug. 10, 2012 from <[URL:http://www.precedex.com/wp-content/uploads/2010/11/Precedex_PI.pdf](http://www.precedex.com/wp-content/uploads/2010/11/Precedex_PI.pdf)>, pp. 1-24.

(Continued)

Primary Examiner — Savitha Rao*Assistant Examiner* — Gregg Polansky(74) *Attorney, Agent, or Firm* — Baker Botts LLP(57) **ABSTRACT**

The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.